Accurate Nonendoscopic Detection of Early Esophageal Squamous Malignant Lesions Using Sponge-Based Methylated DNA Biomarkers.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 40844617.
- Also identified by DOI 10.14309/ajg.0000000000003745.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Early detection of esophageal squamous cell carcinoma (ESCC) significantly improves patient quality of life and outcomes. We aimed to train and validate a predictive algorithm using methylated DNA markers (MDMs) based on encapsulated sponge cell collection device (CCD) samples. CCD samples in the training set (n = 120) were taken from 2 medical centers, and those in the validation set (n = 70) were prospectively collected from another medical center. The case group contained a diverse range of esophageal high-grade lesions, including high-grade intraepithelial neoplasia (HGIN), early ESCC, and advanced ESCC. The algorithms were trained on the training set and tested to evaluate diagnostic performance in a prospective validation set. The MDM model was constructed using logistic regression with 2 MDMs (OTOP2 and KCNA3). The areas under the receiver operating characteristic curves were 0.933 (95% confidence interval [CI] 0.881-0.986) and 0.911 (95% CI 0.841-0.981) in the training and validation sets, respectively. The overall sensitivity was 90.0% at a specificity of 91.4% in the training set. The sensitivity was 90.0%, 95.0%, and 90.0% for HGIN, early ESCC, and advanced ESCC in the training set, respectively. The sensitivity and specificity were 87.5% and 86.7% in the validation set, respectively. The areas under the receiver operating characteristic curves for the complex model that included the 2 MDMs and age were 0.961 (95% CI, 0.920-1.000) and 0.940 (95% CI, 0.889-0.990) in the training and validation sets, respectively. The assay of MDMs in CCD samples offers a highly accurate method of predicting HGIN/ESCC, thereby providing the potential for early diagnosis and screening for HGIN/ESCC.